WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced the launch of the Auto-Pure 2400 liquid handler from Allsheng for use with the T-SPOT.TB test. The Auto-Pure 2400 platform ...
Background: Diagnosis and treatment of latent tuberculosis infection (LTBI) is the most effective strategy to control tuberculosis (TB) among patients with HIV infection. The tuberculin skin test (TST ...
Revvity, Inc. (NYSE:RVTY) shares are trading higher on Wednesday. The company announced today that the U.S. Food and Drug Administration has approved its Auto-Pure 2400 liquid handling platform, ...
The US Food and Drug Administration (FDA) has granted approval for Revvity’s Auto-Pure 2400 liquid handling platform, used in conjunction with the T-SPOT.TB test. This approval introduces an ...
FDA approves leading solution for latent tuberculosis diagnostics, advancing global effort to fight infectious diseases “The integration of the Auto-Pure 2400 platform with the T-SPOT.TB test gives ...
Tuberculosis (TB) remains a leading cause of illness and death among children worldwide, with nearly 1.3 million cases estimated in 2023 and more than half going undiagnosed. Current diagnostic tools, ...
OXFORD, United Kingdom and MARLBOROUGH, Mass., April 21, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company, today announced that it has ...
(RTTNews) - Revvity, Inc. (RVTY), Wednesday said that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT. tuberculosis (TB) test. "The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results